The Role of Anti-Phosphatidylserine/Prothrombin Antibodies in Thrombotic Manifestations of Systemic Lupus Erythematosus Patients by Konstantinos Tselios et al.
Positive anti-PS/PT antibodies (>18 U/
ml) were detected in 11/35 patients (31.4%), 
7 with IgG anti-PS/PT, 1 with IgM anti-PS/
PT, and 3 with concomitant IgM and IgG 
anti-PS/PT. From these patients, seven had a 
recent history of vascular thrombosis, while 
the remaining four had other aPL-related 
symptoms and end-stage renal disease 
(1/11), recurrent serositis (2/11), and false 
positive serological reactions for syphilis 
(1/11) respectively. It should be mentioned 
that these four patients had the lower titers 
of anti-PS/PT antibodies (marginally posi-
tive). Ten out of 11 patients were simultane-
ously positive for other aPL, such as ACA 
and anti-b2GPI antibodies. All patients with 
thrombosis were premenopausal women and 
had central nervous system involvement (4/7 
multiple infarcts, 1/7 psychosis, 1/7 seizures, 
and 1/7 posterior reversible leukoencepha-
lopathy syndrome, PRES). Of note, the three 
latter patients had no visible infarcts in brain 
MRI but detectable cerebral flow abnormali-
ties in single-photon emission computed 
tomography (SPECT). None of these patients 
had traditional atherosclerotic risk factors.
High titers of anti-PS/PT antibodies 
(IgM and IgG) were also detected in the sole 
non-lupus patient in three separate cases. 
This patient manifested cerebrovascular 
disease (multiple infarcts), in the absence 
of atherosclerotic risk factors and other aPL. 
In this case a diagnosis of APS was made, 
based in the presence of these antibodies.
These findings come in agreement 
with previous reports demonstrating that 
the anti-PS/PT antibodies are strongly 
related to venous and/or arterial throm-
botic manifestations in SLE patients and, 
particularly, cerebral infarctions (Nojima 
et al., 2006; Nojima et al., 2004). On a 
pathophysiologic basis, a possible syner-
gistic action of the anti-PS/PT, ACA, and 
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Sir,
In their recent article, published in Frontiers 
in Neurology, Mullen et al. (2012) dem-
onstrated that anti-phosphatidylserine/
prothrombin (PS/PT) antibodies are 
independently associated with stroke or 
death in non-antiphospholipid syndrome 
(APS) patients with transient ischemic 
attacks (TIA). Despite thorough statistics, 
the authors mention that these findings 
should be cautiously interpreted, since 
only two patients had positive IgG anti-
PS/PT antibodies and a clinical event. We 
have recently assessed the influence of this 
antiphospholipid antibody (aPL) specificity 
in the clinical phenotype of systemic lupus 
erythematosus (SLE) patients.
In this regard, we evaluated 35 lupus 
patients (33 females/2 males, mean age 
37.5 ± 8.8 years, mean disease duration 
103.8 ± 55.1 months) and one female non-
lupus patient (33 years old), according to a 
previous history of thrombotic complica-
tions (arterial and/or venous thrombosis, 
spontaneous abortions) and other aPL-
related manifestations, such as thrombocy-
topenia and livedo reticularis. Anti-PS/PT 
antibodies were measured, shortly after the 
clinical event, by ELISA (AESKULISA, Serin 
Prothrombin GM, REF 3226). Other aPL 
specificities, such as anticardiolipin anti-
bodies (ACA), anti-b2GPI antibodies, and 
lupus anticoagulant (LA) were also assessed.
anti-b2GPI antibodies in the induction 
of ADP-mediated platelet aggregation 
has been proposed (Nojima et al., 2004). 
In accordance with these results, Syuto 
et al. (2009) showed that these antibodies 
are more frequently (and in higher titers) 
detected in patients with neuropsychiatric 
SLE in general.
Our results, although restricted in 
SLE, confirm the findings of Mullen et al. 
(2012) that anti-PS/PT antibodies may 
serve as a surrogate marker for unfavora-
ble outcome in TIA and may represent 
a subsequent stage in disease evolution 
in lupus patients. Given that, in many 
patients, TIA may not become clinically 
apparent, it could be hypothesized that 
anti-PS/PT antibodies (present in a lupus 
patient with quiescent TIA) may lead, 
over time, to multiple infarcts or to sub-
clinical cerebral flow disturbances, which 
can predispose to the development of 
other neuropsychiatric SLE features. The 
authors also underline that it is difficult to 
determine if the mechanism behind anti-
PS/PT antibodies and cerebrovascular 
events is primarily thrombotic or athero-
sclerotic. In our study, where all patients 
were premenopausal women and had no 
traditional atherosclerotic risk factors, it 
could be assumed that thrombosis, rather 
than atherosclerosis, represents the main 
pathophysiologic mechanism.
In conclusion, anti-PS/PT antibodies 
seem to be strongly related to ischemic/
thrombotic cerebrovascular events. 
Evaluation of their predictive ability and 
stratification of patients with TIA, in large 
scale prospective studies, is warranted.
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